Pre-configured and Validated Solution Reduces the Cost and Time
Associated With Implementation
FOSTER CITY, Calif.--(BUSINESS WIRE)--Sept. 11, 2007--Applied
Biosystems (NYSE:ABI), an Applera Corporation business, today
announced a new laboratory information management system (LIMS) that
is expected to help pharmaceutical companies maintain regulatory
compliance and decrease the cost of managing their manufacturing
operations. The SQL*LIMS(R) Plug and Play Pharma Package(TM) solution
is a pre-configured and validated LIMS developed specifically for the
pharmaceutical industry that has been shown to reduce up-to 85% of the
cost and as much as 75% of the time associated with deployment(1).
Software-based LIMS solutions are used by pharmaceutical companies
to manage their drug development and manufacturing processes. This
includes tracking raw materials and samples as they enter and travel
the laboratory workflow. Maintaining best practices and consistency in
these operations are necessary for complying with regulatory
requirements and ensuring a safe and reliable supply of pharmaceutical
products.
The deployment and validation of LIMS software has traditionally
been expensive and time consuming. The validation process alone
requires that a company audit the LIMS system to demonstrate that it
adheres to specific national and international regulations such as
operational procedures, security definitions, and testing methods. As
a result, considerable time and expense are often spent in designing,
customizing, and validating traditional LIMS systems, which can
significantly increase the total cost of the overall solution.
Analysis conducted by Applied Biosystems indicates that a typical
LIMS implementation takes approximately eight months, with most of
that time spent configuring and validating the system. Because
SQL*LIMS Plug and Play Pharma Package is specifically designed and
validated for the pharmaceutical manufacturing industry, Applied
Biosystems' customers have been able to implement the system in as
little as two months.
Kern Pharma, S.L, a pharmaceutical development and manufacturing
company based in Spain is one of the first organizations to implement
the SQL*LIMS Plug and Play Pharma Package. This particular
pharmaceutical company was attracted to the solution's out-of-the-box
functionality that allows it to be implemented with minimal
reallocation of human resources away from their primary manufacturing
responsibilities.
"What makes SQL*LIMS Plug and Play Pharma Package unique is that
it arrives ready to deploy, with the operational functionality
required for managing the pharmaceutical manufacturing process," said
Albert Almajano, IT project manager at Kern Pharma. "We expect that
SQL*LIMS Plug and Play Pharma Package will become an integral part of
our ongoing efforts to improve efficiency and maintain regulatory
compliance in our drug development and manufacturing operations."
Applied Biosystems designed SQL*LIMS Plug and Play Pharma Package
as a complete solution that integrates critical functions involved in
drug manufacturing operations with the computer hardware and an Oracle
database that enables distribution across an enterprise. The
pre-configured functionality enables system administrators to easily
activate user definitions, security parameters, reporting templates
and testing methods issued by national and international regulatory
bodies. This can help pharmaceutical companies who are upgrading their
existing LIMS as well as those who are new to manufacturing to quickly
implement a validated system that incorporates industry best practices
and meets regulatory requirements.
"Pharmaceutical companies are too often spending excessive time
and money on building and implementing business solutions that require
skill sets or other cost-related resources that take away from their
core business purpose," said John Bainbridge, general manager for the
LIMS business at Applied Biosystems. "To help these customers, we've
taken everything Applied Biosystems has learned about laboratory
information management systems and have packaged it into a complete
solution that significantly decreases the time and costs associated
with LIMS deployments. This enables pharmaceutical companies to focus
on what they do best, which is developing and manufacturing drugs."
Applied Biosystems has been a global leader in providing LIMS
technology for more than 25 years. Today, more than 30,000
professionals worldwide use the company's SQL*LIMS(R) Software in
industries as diverse as pharmaceuticals, chemical and petrochemical
manufacturing, environmental science, food and beverage production,
and forensic analysis. For more information, please visit:
http://info.appliedbiosystems.com/sqllims.
About Applera Corporation and Applied Biosystems
Applera Corporation consists of two operating groups. The Applied
Biosystems Group serves the life science industry and research
community by developing and marketing instrument-based systems,
consumables, software, and services. Customers use these tools to
analyze nucleic acids (DNA and RNA), small molecules, and proteins to
make scientific discoveries and develop new pharmaceuticals. Applied
Biosystems' products also serve the needs of some markets outside of
life science research, which we refer to as "applied markets," such as
the fields of: human identity testing (forensic and paternity
testing); biosecurity, which refers to products needed in response to
the threat of biological terrorism and other malicious, accidental,
and natural biological dangers; and quality and safety testing, for
example in food and the environment. Applied Biosystems is
headquartered in Foster City, CA, and reported sales of approximately
$2.1 billion during fiscal 2007. The Celera Group is primarily a
molecular diagnostics business that is using proprietary genomics and
proteomics discovery platforms to identify and validate novel
diagnostic markers, and is developing diagnostic products based on
these markers as well as other known markers. Celera maintains a
strategic alliance with Abbott for the development and
commercialization of molecular, or nucleic acid-based, diagnostic
products, and it is also developing new diagnostic products outside of
this alliance. Through its genomics and proteomics research efforts,
Celera is also discovering and validating therapeutic targets, and it
is seeking strategic partnerships to develop therapeutic products
based on these discovered targets. Information about Applera
Corporation, including reports and other information filed by the
company with the Securities and Exchange Commission, is available at
http://www.applera.com, or by telephoning 800.762.6923. Information
about Applied Biosystems is available at
http://www.appliedbiosystems.com.
Applied Biosystems Forward Looking Statements
Certain statements in this press release are forward-looking.
These may be identified by the use of forward-looking words or phrases
such as "should, "planned," and "expect," among others. These
forward-looking statements are based on Applera Corporation's current
expectations. The Private Securities Litigation Reform Act of 1995
provides a "safe harbor" for such forward-looking statements. In order
to comply with the terms of the safe harbor, Applera Corporation notes
that a variety of factors could cause actual results and experience to
differ materially from the anticipated results or other expectations
expressed in such forward-looking statements. These factors include
but are not limited to: (1) rapidly changing technology and dependence
on the development and customer acceptance of new products; (2) sales
dependent on customers' capital spending policies and
government-sponsored research; and (3) other factors that might be
described from time to time in Applera Corporation's filings with the
Securities and Exchange Commission. All information in this press
release is as of the date of the release, and Applera does not
undertake any duty to update this information, including any
forward-looking statements, unless required by law.
(1) The reduction of cost and time estimates are based on internal
Applied Biosystems test results.
Applera, Applied Biosystems, AB (Design), and SQL*LIMS are
registered trademarks of Applera Corporation or its subsidiaries in
the US and/or certain other countries.
(C)Copyright 2007. Applied Biosystems. All rights reserved.
MULTIMEDIA AVAILABLE:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5489581
CONTACT: Applied Biosystems
Colin Sanford, 203-661-0372 (Media)
colin.sanford@appliedbiosystems.com
Peter Dworkin, 650-554-2479 (Investors)
dworkipg@appliedbiosystems.com
SOURCE: Applied Biosystems